Observational studyJapanese journal of clinical oncology2025

Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression in elderly patients: a subgroup analysis of HOT/NJLCG2001.

Kazunari Tateishi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.